Financial disclosure for associate editors of the Cleveland Clinic Journal of Medicine

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), the Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following associate editors of the Cleveland Clinic Journal of Medicine have indicated that they may have a relationship which, in the context of their contributions, could be perceived as a conflict of interest:

DANIEL J. BROTMAN, MD

Advisory board: Canyon Pharmaceuticals, Cubist Pharmaceuticals, Sanofi-Aventis, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, EMCREG International, Otsuka America Pharmaceutical, Ortho-McNeil Pharmaceuticals, Johnson & Johnson Hospitalist leadership panel: Quantia Communications

Research support: Siemens Healthcare Diagnostics

GARY FRANCIS, MD Data and safety monitoring board: Novartis

AMIR K. JAFFER, MD Consulting: Canyon Pharmaceuticals Consulting; teaching and speaking: Sanofi-Aventis Pharmaceuticals

MANDY C. LEONARD, PharmD Consulting; teaching and speaking; advisory committee, or review panel: Amaen

ANGELO A. LICATA, MD, PhD Consulting; teaching and speaking; independent contractor: Novartis, Eli Lilly, Amgen

ATUL C. MEHTA, MD Advisory board: PneumRx Medical Potential stock option: SuperDimension

FRANKLIN A. MICHOTA, MD Consulting; teaching and speaking: Sanofi-Aventis Pharmaceuticals, Otsuka America Pharmaceutical

CHRISTIAN NASR. MD Teaching and speaking: Sanofi-Aventis Pharmaceuticals, Merck & Co

BERNARD J. SILVER, MD Teaching and speaking: Talecris Biotherapeutics

TYLER STEVENS, MD Consulting: Boston Scientific Research funding: Abbott Pharmaceuticals

THEODORE SUH, MD, PhD, MHSc Teaching and speaking: Novartis Ownership interest: GlaxoSmithKline

DONALD G. VIDT, MD Independent contractor (research), trial design: AstraZeneca

WILLIAM S. WILKE, MD Consulting: UCB, Pfizer

All other associate editors have indicated they have no relationship that in the context of their contributions could be perceived as a conflict of interest. Disclosures for editors and editorial staff can be found on page 340.